Therapeutic Areas

Our primary focus lies in identifying and advancing first-in-class therapeutics with the potential to address unmet medical needs. Our therapeutic area encompasses therapies for oncology, Alzheimer's disease, and other CNS diseases including Parkinson's disease.

Oncology

Our cancer therapy, DM5167, a second-generation PARP1 selective inhibitor, is currently undergoing review by the Institutional Review Board (IRB) for phase 1 clinical trials in Korea. Preclinical data highlight significant advancements of DM5167 over first-generation PARP inhibitors, in efficacy, toxicity profiles, and blood-brain barrier (BBB) penetration. Compared to AZD 5305, AstraZeneca's PARP1 selective inhibitor in phase 2 trials, DM5167 demonstrates exceptional hematological toxicity profiles and BBB penetration indicators with the brain-to-plasma concentration ratio (Kp, brain) of 0.89, making it an ideal candidate for combination therapies. DM5167 targets cancers with BRCA mutation and/or homologous recombination deficiency (HRD), as well as metastatic brain tumors.

Neurodegeneration

Our Alzheimer's disease candidate, DM3159, targets neuroprotection and neurogenesis as a disease-modifying therapy, diverging from traditional approaches focused on beta-amyloid or tau protein for symptomatic relief. Early-stage preclinical data for DM3159 indicates differentiated efficacy, toxicity, and BBB penetration. Recognized by the Korean government, DigmBio has received grants to advance not only Alzheimer's disease treatments but also those for CNS disorders including Parkinson's disease.